HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy

Celia Chui, Peter K. Cheung, Chanson J. Brumme, Theresa Mo, Zabrina L. Brumme, Julio S G Montaner, Andrew David Badley, P. Richard Harrigan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

VprR77Q has been associated with long-term nonprogressive (LTNP) HIV infection. We wished to investigate the prevalence, clinical correlates, and effect on treatment response of VprR77Q in a cohort of antiretroviral-naïve individuals initiating highly active antiretroviral therapy (HAART). Baseline plasma samples from 728 subjects were genotyped using RT-PCR and direct DNA sequencing. Cox proportional hazards regression was used to model the effects of VprR77Q on virologic and immunologic responses, and survival following initiation of HAART, over a median 4.5 years follow-up. We found that 308 subjects (42.3%) harbored VprR77Q alone or in combination with another amino acid, while 420 (57.7%) harbored an amino acid other than Q. A cross-sectional analysis found no correlation between R77Q and baseline plasma viral load (pVL), CD4 count, diagnosis of AIDS, or sociodemographic characteristics including age, gender, and history of injection drug use (p > 0.1). In multivariate analyses, no significant associations between VprR77Q and initial pVL and CD4 responses to HAART or survival following initiation of treatment were observed (p > 0.1). The high prevalence and the lack of association with pretherapy clinical parameters in this cohort argue against an association of R77Q with LTNP status. These results do not support an association between R77Q and HAART response.

Original languageEnglish (US)
Pages (from-to)615-618
Number of pages4
JournalAIDS Research and Human Retroviruses
Volume22
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Highly Active Antiretroviral Therapy
HIV
Mutation
Viral Load
Amino Acids
CD4 Lymphocyte Count
DNA Sequence Analysis
HIV Infections
Acquired Immunodeficiency Syndrome
Multivariate Analysis
Cross-Sectional Studies
Polymerase Chain Reaction
Injections
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Chui, C., Cheung, P. K., Brumme, C. J., Mo, T., Brumme, Z. L., Montaner, J. S. G., ... Harrigan, P. R. (2006). HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. AIDS Research and Human Retroviruses, 22(7), 615-618. https://doi.org/10.1089/aid.2006.22.615

HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. / Chui, Celia; Cheung, Peter K.; Brumme, Chanson J.; Mo, Theresa; Brumme, Zabrina L.; Montaner, Julio S G; Badley, Andrew David; Harrigan, P. Richard.

In: AIDS Research and Human Retroviruses, Vol. 22, No. 7, 07.2006, p. 615-618.

Research output: Contribution to journalArticle

Chui, Celia ; Cheung, Peter K. ; Brumme, Chanson J. ; Mo, Theresa ; Brumme, Zabrina L. ; Montaner, Julio S G ; Badley, Andrew David ; Harrigan, P. Richard. / HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. In: AIDS Research and Human Retroviruses. 2006 ; Vol. 22, No. 7. pp. 615-618.
@article{b5ea156302454c358e6dd11358c53097,
title = "HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy",
abstract = "VprR77Q has been associated with long-term nonprogressive (LTNP) HIV infection. We wished to investigate the prevalence, clinical correlates, and effect on treatment response of VprR77Q in a cohort of antiretroviral-na{\"i}ve individuals initiating highly active antiretroviral therapy (HAART). Baseline plasma samples from 728 subjects were genotyped using RT-PCR and direct DNA sequencing. Cox proportional hazards regression was used to model the effects of VprR77Q on virologic and immunologic responses, and survival following initiation of HAART, over a median 4.5 years follow-up. We found that 308 subjects (42.3{\%}) harbored VprR77Q alone or in combination with another amino acid, while 420 (57.7{\%}) harbored an amino acid other than Q. A cross-sectional analysis found no correlation between R77Q and baseline plasma viral load (pVL), CD4 count, diagnosis of AIDS, or sociodemographic characteristics including age, gender, and history of injection drug use (p > 0.1). In multivariate analyses, no significant associations between VprR77Q and initial pVL and CD4 responses to HAART or survival following initiation of treatment were observed (p > 0.1). The high prevalence and the lack of association with pretherapy clinical parameters in this cohort argue against an association of R77Q with LTNP status. These results do not support an association between R77Q and HAART response.",
author = "Celia Chui and Cheung, {Peter K.} and Brumme, {Chanson J.} and Theresa Mo and Brumme, {Zabrina L.} and Montaner, {Julio S G} and Badley, {Andrew David} and Harrigan, {P. Richard}",
year = "2006",
month = "7",
doi = "10.1089/aid.2006.22.615",
language = "English (US)",
volume = "22",
pages = "615--618",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy

AU - Chui, Celia

AU - Cheung, Peter K.

AU - Brumme, Chanson J.

AU - Mo, Theresa

AU - Brumme, Zabrina L.

AU - Montaner, Julio S G

AU - Badley, Andrew David

AU - Harrigan, P. Richard

PY - 2006/7

Y1 - 2006/7

N2 - VprR77Q has been associated with long-term nonprogressive (LTNP) HIV infection. We wished to investigate the prevalence, clinical correlates, and effect on treatment response of VprR77Q in a cohort of antiretroviral-naïve individuals initiating highly active antiretroviral therapy (HAART). Baseline plasma samples from 728 subjects were genotyped using RT-PCR and direct DNA sequencing. Cox proportional hazards regression was used to model the effects of VprR77Q on virologic and immunologic responses, and survival following initiation of HAART, over a median 4.5 years follow-up. We found that 308 subjects (42.3%) harbored VprR77Q alone or in combination with another amino acid, while 420 (57.7%) harbored an amino acid other than Q. A cross-sectional analysis found no correlation between R77Q and baseline plasma viral load (pVL), CD4 count, diagnosis of AIDS, or sociodemographic characteristics including age, gender, and history of injection drug use (p > 0.1). In multivariate analyses, no significant associations between VprR77Q and initial pVL and CD4 responses to HAART or survival following initiation of treatment were observed (p > 0.1). The high prevalence and the lack of association with pretherapy clinical parameters in this cohort argue against an association of R77Q with LTNP status. These results do not support an association between R77Q and HAART response.

AB - VprR77Q has been associated with long-term nonprogressive (LTNP) HIV infection. We wished to investigate the prevalence, clinical correlates, and effect on treatment response of VprR77Q in a cohort of antiretroviral-naïve individuals initiating highly active antiretroviral therapy (HAART). Baseline plasma samples from 728 subjects were genotyped using RT-PCR and direct DNA sequencing. Cox proportional hazards regression was used to model the effects of VprR77Q on virologic and immunologic responses, and survival following initiation of HAART, over a median 4.5 years follow-up. We found that 308 subjects (42.3%) harbored VprR77Q alone or in combination with another amino acid, while 420 (57.7%) harbored an amino acid other than Q. A cross-sectional analysis found no correlation between R77Q and baseline plasma viral load (pVL), CD4 count, diagnosis of AIDS, or sociodemographic characteristics including age, gender, and history of injection drug use (p > 0.1). In multivariate analyses, no significant associations between VprR77Q and initial pVL and CD4 responses to HAART or survival following initiation of treatment were observed (p > 0.1). The high prevalence and the lack of association with pretherapy clinical parameters in this cohort argue against an association of R77Q with LTNP status. These results do not support an association between R77Q and HAART response.

UR - http://www.scopus.com/inward/record.url?scp=33745951410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745951410&partnerID=8YFLogxK

U2 - 10.1089/aid.2006.22.615

DO - 10.1089/aid.2006.22.615

M3 - Article

VL - 22

SP - 615

EP - 618

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 7

ER -